Biopharma AI
ByIs AI Becoming Big Pharma’s Frontline Tool for Early Cancer Detection? Bristol Myers Squibb and Microsoft Signal a Strategic Shift
Executive Summary Bristol Myers Squibb (BMS) has entered a strategic partnership with Microsoft to advance AI-driven early detection…
How Will Hippocratic AI Leverage Grove AI to Accelerate Trial Efficiency and Patient Engagement?
January 22, 2026 — Global — BioNexAI Market Insights reports that Hippocratic AI, a leading AI innovator, has…
Is AstraZeneca’s Acquisition of Modella AI at JPM 2026 a Signal That Pharma Is Internalizing AI for R&D?
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial intelligence capabilities, announcing…
Is the $1 Billion Lilly–NVIDIA Alliance at JPM26 the Turning Point Where AI Becomes Industrial-Scale Drug Discovery?
San Francisco | January 12, 2026 The 44th Annual J.P. Morgan Healthcare Conference (JPM26) opened with a defining…
Is China Outpacing the Global Biopharma Cycle? Innovation and Deal Momentum Accelerate
23 January 2026 Executive Summary China’s biopharma sector is continuing to advance at remarkable speed, with recent analyses…
Is China Becoming a Power Center for AI-Led Drug Discovery? Insilico Medicine Strikes $66 Million NLRP3 Licensing Deal
23 January 2026 Executive Summary Artificial-intelligence-driven drug developer Insilico Medicine has entered into a $66 million licensing agreement…
